Head and Neck Squamous Cell Carcinoma Clinical Trials in Washington D.C., District of Columbia

6 studies are recruiting for head and neck squamous cell carcinoma in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

   This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chem…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   George Washington University Medical Center, Washington D.C., District of Columbia

   Locations

   679 in total

   Run by

   ECOG-ACRIN Cancer Research Group

   See if you can join NCT02734537 on ClinicalTrials.gov

2. Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

   This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral mucositis (inflammation and mouth sores) is a common side effect…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   George Washington University Medical Center, Washington D.C., District of Columbia

   Locations

   153 in total

   Run by

   NRG Oncology

   See if you can join NCT06532279 on ClinicalTrials.gov

3. A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

   This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Site 108, Washington D.C., District of Columbia

   Locations

   205 in total

   Run by

   Merus B.V.

   See if you can join NCT06525220 on ClinicalTrials.gov

4. Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

   This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for pos…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   5 in total

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT05977907 on ClinicalTrials.gov

5. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Georgetown University Medical Center, Washington D.C., District of Columbia

   Locations

   39 in total

   Run by

   SystImmune Inc.

   See if you can join NCT05983432 on ClinicalTrials.gov

6. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

   This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   The George Washington University Cancer Center (site 212), Washington D.C., District of Columbia

   Locations

   15 in total

   Run by

   VM Oncology, LLC

   See if you can join NCT03556228 on ClinicalTrials.gov